Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

Rhea-AI Summary

Nkarta (Nasdaq: NKTX) will present a poster at ACR Convergence 2025 in Chicago on Sunday, October 26, 2025, reporting clinical and preclinical data for its investigational therapy NKX019.

Data to be presented show robust CD19+ B‑cell depletion with subsequent B‑cell reconstitution consistent with immune reset in participants with non‑Hodgkin lymphoma, plus preclinical results showing depletion of pathogenic B cells in in vivo lymphoma models and in vitro autoimmune models and trafficking to lymphoid organs.

Poster details: Presenting author Mira Tohmé; time 10:30 AM–12:30 PM CT; room Hall F1; poster number 0014. Nkarta will also exhibit at booth #1801.

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced it will be presenting a poster this Sunday in Chicago at the American College of Rheumatology (ACR) Convergence 2025 meeting.

Nkarta will present clinical data showing that the company’s investigational therapy, NKX019, achieved robust pathogenic B-cell depletion followed by reconstitution of the B cell compartment, consistent with immune reset in participants with non-Hodgkin lymphoma. Additionally, the company will share data from preclinical studies demonstrating that NKX019 effectively depletes pathogenic B cells in both in vivo lymphoma models and in vitro autoimmune disease models, traffics to lymphoid organs, and disseminates across multiple tissues. These data highlight NKX019’s potential as a novel therapeutic approach for B-cell driven autoimmune diseases.

Our accepted abstract can be accessed on the ACR Convergence 2025 website. 

“Millions of patients in the United States are living with autoimmune diseases driven by pathological B cells, and current treatment paradigms are often inadequate or limited by toxicities, leaving patients with few options,” said Mira Tohmé, PhD, associate director of translational research at Nkarta, who will present the poster. “Our data highlight the potential for our engineered, allogeneic NK cells to treat a range of autoimmune diseases by selectively depleting the disease-driving B cells without inducing limiting toxicities.”

Details of the Sunday poster presentation are as follows:

Abstract Title: NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease
Presenting Author: Mira Tohmé (ID: 2762863)
Date: Sunday, October 26
Presentation Time: 10:30 AM - 12:30 PM CT
Room: Hall F1
Session: (0001–0018) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster I
Submission Number: 2130624
Poster Number: 0014

In addition to the poster presentation, Nkarta will exhibit at booth #1801, where attendees can meet with Nkarta representatives to discuss the company’s clinical programs.

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:
Nadir Mahmood
Nkarta, Inc.
nmahmood@nkartatx.com

FAQ

When and where will Nkarta (NKTX) present NKX019 data at ACR Convergence 2025?

Nkarta will present on Sunday, October 26, 2025 in Chicago at ACR Convergence 2025, 10:30 AM–12:30 PM CT in Hall F1.

What clinical findings will Nkarta (NKTX) present about NKX019 at ACR 2025?

The poster reports robust CD19+ B‑cell depletion followed by B‑cell reconstitution consistent with an immune reset in participants with non‑Hodgkin lymphoma.

What preclinical evidence for NKX019 will Nkarta (NKTX) share at ACR Convergence 2025?

Nkarta will share preclinical data showing NKX019 depletes pathogenic B cells in in vivo lymphoma models and in vitro autoimmune disease models, and traffics to lymphoid organs.

Who is presenting Nkarta’s NKX019 poster and how can I find the abstract?

Presenting author is Mira Tohmé; the accepted abstract is available on the ACR Convergence 2025 website (submission number 2130624, poster number 0014).

What are the Nkarta (NKTX) presentation logistics at ACR Convergence 2025?

Poster session: B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster I (session 0001–0018); presentation time 10:30 AM–12:30 PM CT; Nkarta exhibit at booth #1801.